CNBC Pro

Analyst says Pfizer set for 45% upside after strong vaccine trial results

Pedestrians wearing protective masks walk past Pfizer Inc. headquarters on July 22, 2020 in New York City.
Jeenah Moon | | Getty Images

(This story is only for CNBC Pro subscribers)

With Wall Street buzzing about Pfizer and BioNTech's potential coronavirus vaccine, some analysts are telling clients the drugmakers could be due for meaningful upside in the months ahead.

Cantor Fitzgerald analyst Louise Chen wrote that she sees Pfizer's stock climbing to $53 per share, 45% above where it closed on Friday and 32% above where it traded Monday. She has an overweight rating on the shares.

More In Street Calls

CNBC ProGoldman says buy the pullback in oil and other commodities
CNBC ProCiti cuts year-end S&P 500 target, but sees second-half bounce
CNBC ProHere are Monday's biggest analyst calls: Robinhood, Apple, Oracle, Chewy, Deckers, Amazon & more